Evidence map›Paper›PMID 34875702›Full record

ArticleThrombosis and haemostasis2022

Management of DOAC in Patients Undergoing Planned Surgery or Invasive Procedure: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) Position Paper.

Alessandro Squizzato, Daniela Poli, Doris Barcellona, Antonio Ciampa, Elvira Grandone, Cesare Manotti, Marco Moia, Vincenzo Toschi, Alberto Tosetto, Sophie Testa and 1 more

Open access · hybridAbstract readConsensus Statement
In one paragraph

Article in Thrombosis and haemostasis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Alessandro SquizzatoResearch Center on Thromboembolic Disorders and Antithrombotic Therapies, ASST Lariana, University of Insubria, Como, Italy.ORCID 0000-0001-5705-2897
Daniela PoliThrombosis Center, 'Careggi' Hospital, Florence, Italy.
Doris BarcellonaThrombosis and Haemostasis Unit, University of Cagliari, Cagliari, Italy.ORCID 0000-0002-0823-3357
Antonio CiampaHaemostasis Center, 'Moscati' Hospital, Avellino, Italy.
Elvira GrandoneThrombosis and Haemostasis Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.ORCID 0000-0002-8980-9783
Cesare ManottiHaemostasis Center, Hospital of Parma, Parma, Italy.
Marco MoiaHaemophilia and Thrombosis Center, IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
Vincenzo ToschiDepartment of Haematology and Blood Transfusion and Thrombosis Center, Santi Paolo e Carlo Hospital, Milan, Italy.
Alberto TosettoHemophilia and Thrombosis Center, Hematology Department, San Bortolo Hospital, Vicenza, Italy.
Sophie TestaHaemostasis and Thrombosis Center, ASST Cremona, Cremona, Italy.
Scientific Reviewer Committee
Azienda Ospedaliera S.Giuseppe Moscati · ITAzienda Ospedaliero-Universitaria Careggi · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITIstituti Ospitalieri di Cremona · ITOspedale San Bortolo · ITSechenov University · RUUniversity of Cagliari · ITUniversity of Insubria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients on anticoagulant treatment are constantly increasing, with an estimated prevalence in Italy of 2% of the total population. About a quarter of the anticoagulated patients require temporary cessation of direct oral anticoagulants (DOACs) or vitamin K antagonists for a planned intervention within 2 years from anticoagulation inception. Several clinical issues about DOAC interruption remain unanswered: many questions are tentatively addressed daily by thousands of physicians worldwide through an experience-based balancing of thrombotic and bleeding risks. Among possible valuable answers, the Italian Federation of Centers for the diagnosis of thrombotic disorders and the Surveillance of the Antithrombotic therapies (FCSA) proposes some experience-based suggestions and expert opinions. In particular, FCSA provides practical guidance on the following issues: (1) multiparametric assessment of thrombotic and bleeding risks based on patients' individual and surgical risk factor, (2) testing of prothrombin time, activated partial thromboplastin time, and DOAC plasma levels before surgery or invasive procedure, (3) use of heparin, (4) restarting of full-dose DOAC after high risk bleeding surgery, (5) practical nonpharmacological suggestions to manage patients perioperatively. Finally, FCSA suggests creating a multidisciplinary "anticoagulation team" with the aim to define the optimal perioperative management of anticoagulation.

Indexed as

AnticoagulantsAntithrombinsPostoperative HemorrhageThrombosisElective Surgical ProceduresHematologic TestsHumansItalyPatient Care ManagementPerioperative CareRisk AdjustmentVitamin KAnticoagulantsAntithrombinsVitamin K

Identifiers

PMID34875702
PMCPMC8899293
OpenAlexW4200260881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.